Cingulate Inc. (CING) stock
CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW
$4.72+0.97 (+25.87%)
Close on Nov 17, 2026Market cap $68.64MP/E –Yield –
Cingulate free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cingulate's free cash flow for the twelve months ending Jun 30, 2026 was -$20.94M. For fiscal 2025 it was -$17.41M. The highest annual figure on record is -$7.21M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$17.41M | – |
| FY2024 | Dec 31, 2024 | -$18.66M | – |
| FY2023 | Dec 31, 2023 | -$15.26M | – |
| FY2022 | Dec 31, 2022 | -$16.04M | – |
| FY2021 | Dec 31, 2021 | -$11.25M | – |
| FY2020 | Dec 31, 2020 | -$7.21M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.97M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.75M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.24M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.28M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.35M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.87M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.33M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.57M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.74M | – |
See a number that looks wrong?